Skip to main content

Cryptococcus neoformans endocarditis in an immunocompetentpatient a case report

Abstract

Background

Cryptococcus neoformans is an invasive fungal infection commonly affecting immunocompromised patients as pneumonia or meningitis. More rarely, case reports describe Cryptococcus neoformans endocarditis, though nearly exclusively among patients with active immunosuppression, implanted cardiac devices or prosthetic valves.

Case presentation

We report the case of a patient with underlying substance abuse disorder and systolic heart failure presenting with fever, altered mental status, and shower emboli subsequently found to have native tricuspid valve vegetations and blood cultures positive for cryptococcus neoformans in the absence of immunosuppression.

Conclusions

Historically, Cryptococcus neoformans fungemia manifests clinically as pneumonia or meningitis among the immunosuppressed. There have been rare reports of endocarditis in this population and even fewer reports of native valve endocarditis exist. The present case along with mortality reported in prior literature, suggest suspicion must be maintained in the absence of immunosuppression, even in patients with native valves.

Highlights

  • Cryptococcal Endocarditis poses risk in non-immunosuppressed patients

  • Aortic and Mitral Valve most affect by Cryptococcus

  • Mortality remains high in Cryptococcal Endocarditis

  • Tabulated review of available Cryptococcal Endocarditis literature

Peer Review reports

Background

Cryptococcus neoformans (CN) is an encapsulated yeast found throughout the world known to cause nearly half a million deaths per year. Immunocompromised patients are predominantly affected [1, 2]. Most commonly, CN presents as pneumonia or meningitis though rare cases of infective endocarditis are described [3, 4]. Current literature posits a majority of the CN endocarditis in non-immunosuppressed patients in association to implanted cardiac devices and prosthetic valves [5]. Herein, we describe the novel presentation and clinical course in an immunocompetent patient with native heart valves.

Case presentation

A 65-year-old female with a past medical history significant for heart failure with reduced left ventricular ejection fraction, chronic obstructive pulmonary disease, stage III chronic kidney disease and substance abuse disorder presented with altered mental status. On presentation, she had notable bilateral conjunctival hemorrhages, splinter hemorrhages, and signs of hypervolemia to include jugular venous distension and pitting edema of both lower extremities. “Track marks” were evident in the cubital fossa along with scattered hyperpigmented ovaloid lesions consistent with “skin popping” injuries. Admission laboratory results showed elevated blood urea nitrogen 65 mg/dL, hyperkalemia of 6 mmol/L, acute kidney injury (creatinine of 4.93 mg/dL from baseline 1.57 mg/dL) and a urinalysis consistent with urinary tract infection, white blood cell count showed no leukocytosis (WBC 5.6 k/uL), hemoglobin showed anemia (Hgb 10.8 gm/dL), platelets were 172 k/uL, a coagulopathy with prothrombin 16.7 s, international normalized ratio 1.9, liver function showed aspartate aminotransferase of 48 units/L, alanine transaminase 21 units/L, and elevated high sensitivity troponin I 838 ng/L which decreased over the following hospital days. Further, the patient was COVID-19 positive. Dexamethasone, remdesivir, and aztreonam were given at initial presentation. Her urine cultured positive for Proteus mirabilis (10,000 to 100,000 cfu) and antibiotics were narrowed to reported sensitivity on hospital day 2. Nonetheless, she persistently reported chills and demonstrated continued alteration of mental status. Blood cultures were negative.

A transthoracic echocardiogram completed on hospital day 3 for her volume overload and acute decompensated heart failure highlighted interval worsening of her moderate-severe aortic regurgitation and new small mobile echo densities on the ventricular side of the aortic valve, suspicious for vegetation (Fig. 1). Computed tomography of the head on hospital day 3 revealed several foci of hypodensity in the frontal and parietal lobes, confirmed by immediate follow-up MRI to indicate acute infarcts (Fig. 2). Concern for other embolic phenomena prompted CT of the chest, abdomen, and pelvis which returned positive for new nodular density in the left lower lung lobe (Fig. 3) and scattered hypoattenuating nodules in the liver (Fig. 4). An abnormal signal in the pancreatic head not amenable to characterization beyond mass versus embolic sequalae was also noted. Heparin infusion was initiated given a concern for diffuse emboli. A week after admission, blood culture resulted positive for cryptococcus. Anti-fungal coverage with micafungin and flucytosine was initiated immediately. On hospital day 11 the patient developed thrombocytopenia (platelet count 30 k/uL) and heparin infusion was ceased for possible heparin induced thrombocytopenia.

Fig. 1
figure 1

Transthoracic echocardiogram series

Fig. 2
figure 2

MRI Brain demonstrates prominent new left sided frontal and parietal foci consistent with small acute infarction and septic emboli

Fig. 3
figure 3

CT chest, abdomen, pelvis with coalescing regions of opacities and nodular density within the left lower lobe

Fig. 4
figure 4

CT chest, abdomen, pelvis indicating the hypoattenuating liver nodule

Positive Duke’s criteria in the patient included (1) evidence of endocardial involvement on echocardiogram, (2) predisposing risk factor (IVD’s), (3) presence of vascular phenomenon (conjunctival and splinter hemorrhages, septic pulmonary infarct, cerebral emboli) and (4) blood culture positivity. Serum cryptococcal antigen titers returned 1:256 on hospital day 12. After positive antigen titers, Amphotericin was added to flucytosine. On hospital day 13, lumbar puncture revealed an opening pressure of 26 mmHg, glucose 71 mg/dL, protein 32 mg/dL, and lymphocytes 79 microL. Cerebrospinal fluid culture was completed and negative as were Human immunodeficiency virus (HIV) and immunoglobulin panels. Transesophageal echocardiogram was planned for hospital day 17 but the patients worsening mixed septic and cardiogenic shock resulted in respiratory and hemodynamic failure causing death.

Discussion

Rates of fungal endocarditis rate are rising and are estimated to comprise 1–10% of all infective endocarditis with a total of 1.5 to 11.6 cases per 100,000 [6]. The most common fungal infection is Candida albicans (24–46%), followed by Aspergillus (25%) [7]. Fungal endocarditis is typically a progression from initial fungemia when the cardiac valves are seeded. A prominent risk factor among non-immunocompromised hosts is IV-drug use [8].

More frequently, CN infections affect immunocompromised patients. Incidence is 2–7 per 1000 among HIV positive patients in the United States and confers substantial mortality risk at a rate of 12% [9]. Epidemiology of non-immunocompromised hosts and the underlying infection rates of CN is elusive and less clear [10]. The most common underlying risk factors have been described as diabetes mellitus, end-stage renal disease, liver cirrhosis, and IV-drug use [8, 10]. Non-immunocompromised patients have proportionately less CNS involvement and cryptococcemia compared to immunocompromised patients [10].

CN heart disease is previously reported as presentation of mycotic endocarditis, pericarditis, and cardiomyopathy [5, 11, 12]. Many prior cases have involved implantable prosthetic cardiac devices (prosthetic valves or AICD’s). Patients without implanted devices are frequently immunosuppressed. Only 2 prior cases describe patients void of active immunosuppression and implanted cardiac devices. Among these, IVD use is a unifying risk factor [4, 5, 13,14,15,16,17,18,19,20,21].Diagnosis of fungal endocarditis historically hinges on the Duke Criteria which may preclude a diagnosis if the infection is caused by nontypical microorganisms. In this vain, it remains imperative for the clinician to maintain high index of suspicion in patients with risk factors [22]. In cases of CN endocarditis, a majority of blood cultures will return positive (Table 1).

Table 1 Literature review of published cases with Cryptococcous neoformans endocarditis

Table 1 summarizes characteristics in the previously available literature CN endocarditis cases. Patient age ranges 4 years to 65 years old. 10 males and 2 females have been affected. Common symptoms at presentation include fever, pulmonary complaints, and delirium. The most common comorbidities include chronic kidney disease, immunosuppression, valvular disease and intravenous drug use. Immunosuppressed patients are more often infected. Non-suppressed patients frequently had prosthetic heart valves. To date, only the aortic and mitral valves have been implicated. 3 cases of immune-competent patients without a prosthetic valve are known. Treatment has included amphotericin B. in every case. Common medical complications include meningitis and cerebral infarction. Death occurred in 5 out of 12 cases.

Neurologic complications of Cryptococcus n. endocarditis are common, often manifesting as fungal meningitis, cerebral infarctions, or septic emboli (Table 1). Lumbar puncture should be performed to exclude CNS infiltration. In bacterial infective endocarditis, acute ischemic strokes are the most common sequalae, noted in 30–40% of cases. Cerebral infarction (27%), meningitis (1–20%), septic emboli (2–4%) and abscess (1–7%) are other frequent complications. Paucity of literature exists detailing incidence of neurologic involvement in patients with fungal endocarditis [22], though we have documented septic emboli, strokes, and meningitis in our present review.

Availability of data and material

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Abbreviations

CN:

Cryptococcus neoformans

HIV:

Human immunodeficiency virus

References

  1. Coelho C, Bocca AL, Casadevall A. Chapter one—the tools for virulence of Cryptococcus neoformans. In: Sariaslani S, Gadd GM, editors. Advances in applied microbiology 2014;87:1–41.

  2. Levitz SM. The Ecology of Cryptococcus neoformans and the epidemiology of Cryptococcosis. Rev Infect Dis. 1991;1(6):1163–9. 13(.

    Article  Google Scholar 

  3. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis. 1995;21(1)(1):28–34.

    Article  CAS  Google Scholar 

  4. Nakajima Akihiro A, Makoto K, Osamu M, Yoshiyasu S, Tsunenari Y, Taishi, et al. Predictors for rapid progression of coronary calcification: an optical coherence tomography study. J Am Heart Assoc. 2021;10(3):e019235.

    Article  Google Scholar 

  5. Alhaji M, Sadikot RT. Cryptococcal endocarditis. South Med J. 2011;104(5):363–4.

    Article  Google Scholar 

  6. Sajjadi F, Soeizi M, Abed M, Krause T. Fungal endocarditis: a case of candida glabrata endocarditis. Health Prim Car. 2020;4(2):4–5.

  7. Badiee P, Amirghofran AA, Ghazi Nour M, Shafa M, Nemati MH. Incidence and outcome of documented fungal endocarditis. Int Cardiovasc Res J. 2014;8(4):152–5.

    Google Scholar 

  8. Poowanawittayakom N, Dutta A, Stock S, Touray S, Ellison RT, Levitz SM. Reemergence of intravenous drug use as risk factor for candidemia, Massachusetts, USA. Emerg Infect Dis. 2018;24(4):631–7.

    Article  Google Scholar 

  9. McKenney J, Smith RM, Chiller TM, Detels R, French A, Margolick J, et al. Prevalence and correlates of cryptococcal antigen positivity among AIDS Patients—United States, 1986–2012. MMWR Morb Mortal Wkly Rep. 2014;11(27):585–7.

    Google Scholar 

  10. Pappas PG. Cryptococcal infections in non-hiv-infected patients. Trans Am Clin Climatol Assoc. 2013;124:61–79.

    Google Scholar 

  11. Mann S, Tobolowsky F, Purohit S, Henao-Martínez A, Bajrovic V, Ramanan P, et al. Cryptococcal pericarditis in a heart transplant recipient. Transpl Infect Dis. 2020;22(6):e13366.

    Article  Google Scholar 

  12. Jones I, Nassau E, Smith P. Cryptococcosis of the heart. Br Heart J. 1965;27(3):462–4.

    Article  CAS  Google Scholar 

  13. Roy M, Ahmad S, Roy AK. Cryptococcus neoformans infective endocarditis of native valves in an immunocompetent host. IDCases. 2018;12:66–70.

    Article  Google Scholar 

  14. Harford CG. Postoperative fungal endocarditis: fungemia, embolism, and therapy. Arch Internal Med. 1974;134(1):116–20.

    Article  CAS  Google Scholar 

  15. Child JS, Macalpin RN, Moyer GH, Shanley JD, Layfield LJ. Coronary ostial embolus and mitral vegetation simulating a left atrial myxoma: a case of probable cryptococcal valvulitis. Clin Cardiol. 1979;2(1):43–8.

    Article  CAS  Google Scholar 

  16. Boden WE, Fisher A, Medeiros A, Benham I, McEnany MT. Bioprosthetic endocarditis due to Cryptococcus neoformans. J Cardiovasc Surg (Torino). 1983;24(2):164–6.

    CAS  Google Scholar 

  17. Blanc V, Lavarde V, Thanh NT, Tri HHQ, Guillemain R, Amrein C, et al. Postoperative Cryptococcus neoformans endocarditi. Clin Microbiol Infect. 1996 Aug;2(1)(1):66–9.

    Article  CAS  Google Scholar 

  18. Banerjee U, Gupta K, Venugopal P. A case of prosthetic valve endocarditis caused by Cryptococcus neoformans var. Neoformans. J Med Vet Mycol. 1997;35(2):139–41.

    Article  CAS  Google Scholar 

  19. Kowatari R, Suzuki Y, Daitoku K, Fukuda I. Cryptococcal infective endocarditis in a child with acute lymphocytic leukaemia. Interact Cardiovasc Thorac Surg. 2019;28(4):642–4.

    Article  Google Scholar 

  20. Altibi A, Asghar S, Jebbawi LA, Battisha A, Kak V. Cryptococcus neoformans automated implantable cardioverter-defibrillator (aicd) endocarditis: a challenging case of a rare fungal endocarditis. J Am Coll Cardiol. 2020;75(11, Supplement 1):2973.

    Article  Google Scholar 

  21. Li Y, He S, Lu Z, Ding C, Wang Q, Li Q, et al. Cryptococcal endocarditis of native valves without immunodeficiency or drug abuse: a case report. J Int Med Res [Internet]. 2020;48(12).

  22. Varghese GM, Sobel JD. Fungal endocarditis. Curr Infect Dis Rep. 2008;10(4):275–9.

    Article  Google Scholar 

Download references

Acknowledgements

There are no further acknowledgements for the present study.

Funding

The present report was generated without funding.

Author information

Authors and Affiliations

Authors

Contributions

CM and DW jointly co-authored the article. CM, DW and SW independently analyzed and compiled findings of the cited literature reviews. All parties are agreement and consent for publication of information contained within the report. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Dylan J. Walter.

Ethics declarations

Ethics approval and consent to participate

This article complies with Georgetown University Ethical Code of Conduct and appropriate steps for identity protection have been taken per guidelines of the office of Regulatory Affairs.

Consent for publication

Consent for publication of laboratory findings and diagnostic imaging, along with all clinical documents related to the present case was obtained from medical power of attorney in written form, available upon request.

Competing interests

The authors have no financial or other competing interests beyond their hospital affiliation.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

McGuire, C.N., Walter, D.J. & Wopperer, S.B. Cryptococcus neoformans endocarditis in an immunocompetentpatient a case report. BMC Cardiovasc Disord 22, 565 (2022). https://doi.org/10.1186/s12872-022-02997-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12872-022-02997-9

Keywords

  • Cryptococcal endocarditis
  • Cryptococcal fungemia cardiac manifestations
  • Cryptococcal infection in heart failure
  • Cryptococcus neoformans valvular disease